GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cohance Lifesciences Ltd (NSE:COHANCE) » Definitions » Profitability Rank

Cohance Lifesciences (NSE:COHANCE) Profitability Rank : 9 (As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Cohance Lifesciences Profitability Rank?

Cohance Lifesciences has the Profitability Rank of 9. It has a higher profitability and may stay that way.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is rated on a scale of 1 to 10 and is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

A higher score indicates superior profitability, with companies rated 7 or above considered to have more robust and sustainable profit generation. Conversely, a score of 3 or lower suggests challenges in generating consistent profits.

Cohance Lifesciences's Operating Margin % for the quarter that ended in Dec. 2024 was 31.69%. As of today, Cohance Lifesciences's Piotroski F-Score is 6.


Competitive Comparison of Cohance Lifesciences's Profitability Rank

For the Drug Manufacturers - Specialty & Generic subindustry, Cohance Lifesciences's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cohance Lifesciences's Profitability Rank Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cohance Lifesciences's Profitability Rank distribution charts can be found below:

* The bar in red indicates where Cohance Lifesciences's Profitability Rank falls into.


;
;

Cohance Lifesciences Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The rank is rated on a scale of 1 to 10. A higher score indicates superior profitability, with companies rated 7 or above considered to have more robust and sustainable profit generation. Conversely, a score of 3 or lower suggests challenges in generating consistent profits.

Cohance Lifesciences has the Profitability Rank of 9. It has a higher profitability and may stay that way.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Cohance Lifesciences's Operating Margin % for the quarter that ended in Dec. 2024 is calculated as:

Operating Margin %=Operating Income (Q: Dec. 2024 ) / Revenue (Q: Dec. 2024 )
=973.5 / 3071.5
=31.69 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

Cohance Lifesciences has an F-score of 6 indicating the company's financial situation is typical for a stable company.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

Warning Sign:

Cohance Lifesciences Ltd operating margin has been in a 5-year decline. The average rate of decline per year is -4.5%.

4. Consistency of the profitability

5. Predictability Rank


Cohance Lifesciences Profitability Rank Related Terms

Thank you for viewing the detailed overview of Cohance Lifesciences's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Cohance Lifesciences Business Description

Traded in Other Exchanges
Address
No. 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSIIC, Raidurg, Hyderabad, TG, IND, 500081
Suven Pharmaceuticals Ltd is involved in developing and manufacturing intermediates, active pharmaceutical ingredients (API), specialty chemicals, and formulated drugs under Contract Research and Manufacturing Services (CRAMS) for global pharmaceutical, biotechnology, and chemical companies. The company operates majorly in the Manufacturing (CRAMS) segment, which includes bulk drugs and intermediates under contract services. Its geographical segments include India, the USA, Europe, and the Rest of the World. The majority of the company's revenue comes from the Europe segment.

Cohance Lifesciences Headlines

No Headlines